LON:HIK Hikma Pharmaceuticals - HIK Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. GBX 1,700 -8.50 (-0.50%) (As of 02/1/2023 11:39 AM ET) Add Compare Share Share Today's Range 1,686▼ 1,713.5050-Day Range 1,481▼ 1,720.5052-Week Range 1,174.50▼ 2,137Volume183,452 shsAverage Volume440,044 shsMarket Capitalization£3.74 billionP/E Ratio1,393.44Dividend Yield2.54%Price TargetGBX 1,712.50 ProfileAnalyst RatingsChartCompetitorsDividendInsider TradesHeadlinesSustainability Hikma Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside2.8% UpsideGBX 1,754 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainability-2.61Upright™ Environmental ScoreNews Sentiment0.25Based on 2 Articles This WeekInsider TradingAcquiring Shares£1.70 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.35 out of 5 stars 1.1 Analyst's Opinion Consensus RatingHikma Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 1,754, Hikma Pharmaceuticals has a forecasted upside of 2.8% from its current price of GBX 1,707.Amount of Analyst CoverageHikma Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for HIK. Previous Next 1.7 Dividend Strength Dividend YieldHikma Pharmaceuticals pays a meaningful dividend of 2.54%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthHikma Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Hikma Pharmaceuticals is 42.65%. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHikma Pharmaceuticals has received a 48.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Abiraterone", "Cancer medication (L01)", "Isosorbide dinitrate", and "HIV medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Hikma Pharmaceuticals is -2.61. Previous Next 1.8 News and Social Media Coverage News SentimentHikma Pharmaceuticals has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Hikma Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for HIK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Hikma Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hikma Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought £17,030 in company stock and sold GBX 0 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Hikma Pharmaceuticals is 1,399.18, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 129.25.Price to Earnings Ratio vs. SectorThe P/E ratio of Hikma Pharmaceuticals is 1,399.18, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 97.98.Price to Earnings Growth RatioHikma Pharmaceuticals has a PEG Ratio of 4.82. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHikma Pharmaceuticals has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Hikma Pharmaceuticals (LON:HIK) StockHikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.Read More Receive HIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HIK Stock News HeadlinesJanuary 31, 2023 | americanbankingnews.comHikma Pharmaceuticals' (HIK) "Buy" Rating Reiterated at CitigroupJanuary 24, 2023 | marketwatch.comGlobal Cancer Cachexia Therapeutics Market 2023 (New Exclusive Report) Size, Growth, Status, Latest Trend Insights to 2029February 1, 2023 | PressReach (Ad)Top Lithium Stock To WatchToday's stock market news features a lithium stock with blue sky potential.January 24, 2023 | marketwatch.comAnaesthetic Medicines Market : Competitive Strategy Analysis and Forecast Values 2023-2028January 23, 2023 | marketwatch.comGlobal Generic Injectables Market Size Growth Rate Analysis 2023 by Production, Revenue, Price, Gross Margin, Countries and Forecast to 2027January 20, 2023 | marketwatch.comTotal Intravenous Anesthesia (TIVA) Market 2023 : Future Trend, Business Strategies, Comprehensive Analysis and Forecast by 2028January 19, 2023 | marketwatch.comAntihypertensive Agents Market Size 2029 Size Estimation, New Investment Opportunities with Top Countries DataJanuary 18, 2023 | marketwatch.comCilostazol Market 2023 : Research Report Analysis Size Share Growth Research Report by Regional and Forecast to 2028February 1, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 18, 2023 | marketwatch.comDoxapram Hydrochloride Injection Market Size [2023-2029] | Industry Share, Growth Factor, Revenue And Trends Outlook ReportJanuary 18, 2023 | marketwatch.comButorphanol Market : A Comprehensive Analysis of the Global Industry from 2023 to 2028, Including Size, Share, Growth, and TrendsJanuary 17, 2023 | marketwatch.comGeneric Injectables Market Size: Overview, Share, Trends with Current Market Scenario, 2029January 15, 2023 | marketwatch.comXerostomia (Dry Mouth Disease) Therapeutics Market 2023 : Research Report, Industry Growth, Competitors Analysis and Forecast 2028January 14, 2023 | marketwatch.comCold Sore Treatment Market Trends, Business Overview, Industry Growth, and Forecast 2023 To 2028January 12, 2023 | marketwatch.comFamotidine Injection Market Size, Share, Growth, Revenue, Demand, Future Potential, and Forecast from 2023 to 2029January 11, 2023 | marketwatch.comAntihistamines Market Size 2023 : Segment Overview, Company Profiles, Regional Analysis and Forecast 2029January 10, 2023 | marketwatch.comDexamethasone for COVID-19 Market 2023 by Industry Growth, Size, Trends, Share, Opportunities and Forecast To 2028January 7, 2023 | marketwatch.comOpioid Use Disorder Market Massive Growth Strikes Due To Technological Innovation During 2023-2028January 5, 2023 | proactiveinvestors.comHikma Pharmaceuticals higher as Citi analysts revise target priceJanuary 3, 2023 | msn.comHikma, Celltrion Healthcare sign licensing agreement for VegzelmaJanuary 3, 2023 | markets.businessinsider.comFTSE 100 Rallies Led By Energy StocksJanuary 3, 2023 | marketwatch.comHikma Pharmaceuticals Launches Xyrem Generic in the U.S.January 3, 2023 | proactiveinvestors.comHikma Pharmaceuticals launches generic version of narcolepsy treatment Xyrem in USDecember 21, 2022 | finance.yahoo.comHikma Pharmaceuticals PLC (LON:HIK) is largely controlled by institutional shareholders who own 50% of the companyDecember 19, 2022 | msn.comDrug shortage ‘isn’t like what we had with baby formula’December 19, 2022 | msn.comGottlieb: Drug shortage ‘isn’t like what we had with baby formula’December 14, 2022 | marketwatch.comHikma Pharmaceuticals falls Wednesday, underperforms marketSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HIK Company Calendar Today2/01/2023Next Earnings (Estimated)2/23/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:HIK CUSIPN/A CIKN/A Webwww.hikma.com Phone+44-20-73992760FaxN/AEmployees8,700Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 1,754 High Stock Price ForecastGBX 2,300 Low Stock Price ForecastGBX 1,350 Forecasted Upside/Downside+0.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio1,393.44 Forward P/E Ratio1,036.99 P/E Growth4.82Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio70.79 Current Ratio2.12 Quick Ratio1.27 Sales & Book Value Annual Sales£2.55 billion Price / Sales1.47 Cash FlowGBX 203.86 per share Price / Cash Flow8.34 Book ValueGBX 988.60 per share Price / Book1.72Miscellaneous Outstanding Shares220,230,000Free FloatN/AMarket Cap£3.74 billion OptionableNot Optionable BetaN/A Key ExecutivesEngineer Said Samih Taleb Darwazah (Age 65)Exec. Chairman & CEO Comp: $2.71MMr. Mazen Samih Taleb Darwazah (Age 64)Exec. Vice Chairman & Pres of MENA Comp: $2.11MMr. Khalid Waleed Hosny Al Nabilsi (Age 50)Chief Financial Officer Mr. Hussein ArkhaghaCompany Sec. & Chief CounselMr. Bassam Wael Rushdi Kanaan CFA (Age 57)CPA, Exec. VP of Corp. Devel. and M&A Ms. Susan RingdalExec. VP of Strategic Planning & Global AffairsMs. Majda LabadiExec. VP of Organisational Devel.Mr. Riad MishlawiPres of InjectablesMr. Brian HoffmannPres of GenericsMr. Samuel ParkGlobal Head of Intellectual Property (IP) & Gen. Counsel for USMore ExecutivesKey CompetitorsMediclinic InternationalLON:MDCBTGLON:BTGDechra PharmaceuticalsLON:DPHAbcamLON:ABCUDG HealthcareLON:UDGView All CompetitorsInsiders & InstitutionsDeneen VojtaBought 1,000 shares on 1/17/2023Total: £1.70 M ($1,703.00/share)Sigurdur OlafssonSold 27,498 sharesTotal: £54.67 M ($1,988.00/share)Douglas HurtBought 1,500 shares on 3/3/2022Total: £2.93 M ($1,954.00/share)View All Insider Transactions HIK Stock - Frequently Asked Questions Should I buy or sell Hikma Pharmaceuticals stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" HIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HIK, but not buy additional shares or sell existing shares. View HIK analyst ratings or view top-rated stocks. What is Hikma Pharmaceuticals' stock price forecast for 2023? 5 brokers have issued 1 year price objectives for Hikma Pharmaceuticals' stock. Their HIK share price forecasts range from GBX 1,350 to GBX 2,300. On average, they expect the company's share price to reach GBX 1,754 in the next year. This suggests a possible upside of 2.8% from the stock's current price. View analysts price targets for HIK or view top-rated stocks among Wall Street analysts. How have HIK shares performed in 2023? Hikma Pharmaceuticals' stock was trading at GBX 1,552 at the beginning of the year. Since then, HIK shares have increased by 10.0% and is now trading at GBX 1,707. View the best growth stocks for 2023 here. When is Hikma Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our HIK earnings forecast. How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals announced a dividend on Thursday, August 4th. Investors of record on Thursday, August 18th will be given a dividend of GBX 0.19 per share on Monday, September 19th. This represents a yield of 0.89%. The ex-dividend date is Thursday, August 18th. The official announcement can be viewed at this link. Read our dividend analysis for HIK. Is Hikma Pharmaceuticals a good dividend stock? Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 0.52 per share and currently has a dividend yield of 2.54%. The dividend payout ratio is 42.65%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for HIK. What other stocks do shareholders of Hikma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC). What is Hikma Pharmaceuticals' stock symbol? Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK." How do I buy shares of Hikma Pharmaceuticals? Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Hikma Pharmaceuticals' stock price today? One share of HIK stock can currently be purchased for approximately GBX 1,707. How much money does Hikma Pharmaceuticals make? Hikma Pharmaceuticals (LON:HIK) has a market capitalization of £3.76 billion and generates £2.55 billion in revenue each year. How many employees does Hikma Pharmaceuticals have? The company employs 8,700 workers across the globe. How can I contact Hikma Pharmaceuticals? Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at +44-20-73992760. This page (LON:HIK) was last updated on 2/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.